Can-Fite BioPharma (NYSE:CANF)soars 87.4% premarket after announcing that the last patient treated under an Open Label Extension program of its concluded Phase II study of Namodenoson in the treatment of hepatocellular carcinoma (HCC), experienced a Complete Response (CR), meaning that all cancer lesions have cleared.
Under treatment with Namodenoson, the patient has now survived five years, during which time the clinical benefits of treatment have included the disappearance of ascites, normal liver function, and the disappearance of peritoneal carcinomatosis leading to complete clearance of all cancer lesions.
In Q1 2022, Can-Fite expects to commence patient enrollment in Phase III trial for Namodenoson in advanced HCC with underlying Child Pugh B7 cirrhosis to support a New Drug Application submission and approval.